Predictive Value of Multimodal MRI in Parkinson's Disease

Chinese PLA General Hospital (301 Hospital)

Status

Enrolling

Conditions

Parkinson's Disease

Deep Brain Stimulation

Magnetic Resonance Imaging

Treatments

Other: Functional magnetic resonance imaging

Device: Deep Brain Stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT05003206

Multimodal MRI DBS-PD

Details and patient eligibility

About

Deep brain stimulation (DBS) is recognized as the most safe and effective neurosurgical method for the treatment of advanced Parkinson's disease. However, the mechanism of relieving motor and non-motor symptoms of Parkinson's disease has not been fully clarified, and the prognosis is significantly different. This study is based on multimodal MRI technique to clarify the mechanism of DBS in relieving motor and non-motor symptoms of Parkinson's disease, and to explore imaging indicators that can predict prognosis, so as to guide the individual and accurate treatment of Parkinson's disease (PD).

Full description

Preoperative and postoperative multimodal MRI scanning 1) equipment: 3TGE 750 MRI 2) sequence: resting state fMRI, DTI, 3DTI, ESWAN, ASL 3) scan status: drug shutdown period ( discontinuation of drugs for Parkinson's disease for at least 12 hours), for patients who can not adhere to MRI scanning after drug withdrawal. Record the dosage of drugs before scanning
Evaluation of motor and non-motor symptoms: pre-operation and 1-year post-operation 1) motor symptoms: pre-operation medication opening and closing period. Postoperative medication off/stimulation off (Med-OFF/DBS-OFF);Med-ON/DBS-OFF;Med-OFF/DBS-ON;Med-ON/DBS-ON
1. overall evaluation of motor function: MDS-UPRDS, H&Y stage
2. balance: Berg balance scale
3. dyskinesia: abnormal involuntary movement scale(AIMS)
4. end-of-dose phenomenon: WOQ19 end-of-dose phenomenon questionnaire
5. daily activity ability: SCHWAB&ENGLAND daily activity scale 2) non-motor symptoms: preoperative drug shutdown period. Postoperative drug shutdown / DBS opening

1. Cognitive function: Mini Mental State Examination scale (MMSE), Montreal Cognitive Assessment scale (MoCA)
2. emotion: Hamilton Depression scale (HAMD), Hamilton anxiety scale (HAMA)
3. Sleep: PD Sleep scale (PDSS), Appleworth sleepiness scale (ESS), REM Sleep Behavioral Disorder questionnaire-Hong Kong (RBDQ-HK)
4. pain: King Parkinson's disease pain scale (KPPS)
5. fatigue: fatigue severity scale (FSS)
6. autonomic nervous function assessment: autonomic nervous scale (SCOPA-AUT) h) quality of life: 39 items Parkinson's disease quality of life questionnaire (PDQ-39) 3.other records: changes in type, dose and mode of use of drugs. Daily equivalent dose of levodopa (tomlinson2010 conversion)

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient with Parkinson's disease
age< 70 years
Underwent bilateral STN-DBS or not
Having complete medical history and clinical follow up
All MRI examination performed according to study protocol
Imaging data can be processed
Signed informed consent obtained from the patient or patient's legally authorized representative;

Exclusion criteria

Parkinson-plus syndrome or secondary parkinsonism
Patients with severe mental disorders such as psychosis, liver and kidney dysfunction, poor blood pressure or blood glucose control, severe depression and substance abuse, low IQ, and acute phase of severe stroke with definite limb dysfunction should also be excluded.